Thank you. Magnus. So the Type A meeting with the FDA was an important and constructive step forward for the Orviglance program. While the FDA continues to require additional clinical evidence for approval, the meeting substantially reduced uncertainty around both the product quality and clinical components of the Complete Response Letter. Several important areas of alignment were established during the discussions, and the FDA acknowledged the significant unmet medical need in patients with severe renal impairment, which is a patient population with limited access to contrast-enhanced MRI. Today, the agency also acknowledged the favorable safety profile of Orviglance and its technical performance as a liver-specific T1-enhancing contrast agent. And importantly, the FDA confirmed that the existing clinical data package retains value and may contribute as supportive evidence in a future submission. On the product quality side, we reached alignment on the proposed strategy to address the observations raised in the CRL, and this is important because it removes a significant area of uncertainty, and FDA expectations are now understood and the implementation activities have already started. Finally, the meeting clarified that the key remaining regulatory question relates to the demonstration of clinical utility. And this was the most important outcome of the meeting regarding the Complete Response Letter. The FDA's recommendation was to conduct a new clinical study with new patients. During the Type A meeting, FDA confirmed that this remains one possible route of approval. However, the agency also acknowledged an alternative approach. FDA indicated that additional clinical evidence could potentially be generated through a new evaluation of the existing SPARKLE image database using a different primary endpoint than originally used. We view this as a significant and encouraging development. Rather than having a single path forward based on a completely new clinical study, there is now the possibility of leveraging the substantial clinical data that have already been generated. Additional work is still required, and our immediate focus is to identify endpoints that appropriately address the FDA's concerns and demonstrate clinical utility. And before initiating any image reading process, we intend to align with the FDA on the selected endpoint through a Type A meeting. So having discussed the regulatory progress for Orviglance, I would now like to spend a few minutes on our second oncology asset, Oncoral.
So while the company's immediate focus remains advancing. Orviglance. Towards approval and partnering, Oncoral continues to represent an important long-term value opportunity.
Over the last decade or so, oncology has seen tremendous progress through targeted therapies and immunotherapies. Despite these advances, chemotherapy continues to be used in the majority of patients with solid tumors and remains a cornerstone of cancer treatment. At the same time, patients are living longer, making treatment burden, cumulative toxicity, and quality of life increasingly important considerations. Regulators, clinicians, and oncology societies are paying greater attention to these aspects when assessing treatment value. This creates a significant opportunity for treatment approaches that preserve anti-tumor efficacy while reducing toxicity and improving quality of life. We believe this trend is highly relevant to Oncoral and forms part of the rationale behind our development strategy. Oncoral is designed to fundamentally change how irinotecan is delivered. Conventional irinotecan is administered intravenously at relatively high doses every few weeks, and this results in high peak drug concentrations that are frequently associated with toxicities, followed by prolonged periods with minimal exposure. Oncoral enables a very different dosing strategy through daily oral administration. The goal is to create a more sustained exposure profile over time. And this approach, sometimes referred to as metronomic dosing, has the potential to improve tolerability while maintaining anti-tumor activity. Sustained exposure may also allow irinotecan to affect not only tumor cells directly, but also biological processes within the tumor microenvironment that are difficult to target with conventional intermittent dosing. So in simple terms, we believe Oncoral may allow us to use a proven chemotherapy in a smarter and potentially more effective way. This slide explains why we believe Oncoral is more than simply an oral formulation of Irinotecan. Many groups have attempted oral irinotecan development over the years. The challenge has been achieving sufficiently predictable pharmacokinetics and bioavailability to support reliable chronic dosing. The proprietary Oncoral tablet technology addresses this challenge and enables daily administration with a pharmacokinetic profile suitable for metronomic treatment. Our Phase 1 studies provided encouraging evidence supporting this concept, and we observed predictable drug exposure, favorable tolerability, and stable disease in a number of heavily pretreated patients. Taken together, these findings support the feasibility of transforming irinotecan from an intermittent infusion therapy into a continuous metronomic treatment strategy. That is why we like to describe Oncoral as a dosing platform rather than a simple reformulation. So Oncoral is more than just another dosage form of irinotecan, and this distinction is important. Oncoral differs from conventional irinotecan in several ways. First, the pharmacology is different because patients receive continuous low-dose exposure rather than intermittent high-dose treatment, as I just described. And second, the biology may be different. Metronomic chemotherapy has been associated with anti-angiogenic and immunomodulatory effects that extend beyond direct tumor killing. Tumor cell killing. And third, the treatment feasibility is different. Daily chronic irinotecan treatment is simply not practical. Using intravenous administration. And finally, the clinical opportunities may be different. This approach could potentially be applicable in maintenance settings and combination regimens where conventional irinotecan is difficult to use. For these reasons, we believe Oncoral should be viewed as a platform, enabling a distinct therapeutic approach rather than merely an oral substitute for existing irinotecan products. Our current development focus is gastric cancer, and this indication represents a significant unmet medical need, and it's an area where irinotecan already has established clinical relevance. An important part of the rationale comes from preclinical data demonstrating synergy between irinotecan and Lonsurf, and these studies suggest greater anti-tumor activity when the two agents are combined than when either is used alone. So this combination is particularly attractive because both treatments are administered orally, creating the possibility of a fully oral treatment regimen. While gastric cancer is our lead indication, we view it as a beginning rather than the end of the opportunity. Irinotecan has established anti-tumor activity across multiple solid tumors and remains included in treatment guidelines for several major cancer types. The broader vision for Oncoral is therefore to apply the daily oral dosing concept wherever irinotecan biology and clinical experience support such an approach, and as shown on this slide, several of these indications represent very substantial patient populations and commercial opportunities.
This gives Oncoral the potential to evolve from a single product opportunity into a broader platform, capable of generating value across multiple cancers. In summary, we are not simply developing an oral Irinotecan product. We are developing a new way of using Irinotecan with the potential to improve patient experience while preserving and potentially enhancing therapeutic benefits. So with that, I will hand back to Magnus to discuss financials and outlook.